IP Library Granted Patent US 8,362,266
Granted Patent B2
US 8,362,266 · App. 12/636,025 · Granted Jan 29, 2013

Method of manufacturing a ruthenium complex

Inventor: Berhhard Keppler (Hockenheim, DE)
Assignee: Niiki Pharma Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,362,266
App. No.
12/636,025
Granted
Jan 29, 2013
Kind
B2
Abstract

A method of making an alkali metal salt of trans-[tetrachlorobis(1H-indazole)ruthenate (III)] is disclosed.

Claims (16)

1. A method of making the compound M[tetrachlorobis(1H-indazole)ruthenate (III)], wherein M is an alkali metal cation, comprising the steps of,

reacting, in an aqueous solution or a mixture of an aqueous solution and a first organic solvent which is water soluble, indazolium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] with an inorganic salt of said alkali metal cation M, to form the compound M[tetrachlorobis(1H-indazole)ruthenate (III)] and an inorganic salt of indazole; and

removing said indazole from said M[tetrachlorobis(1H-indazole)ruthenate (III)] by extraction with a second organic solvent which is not substantially water soluble.

2. A method of making the compound M[tetrachlorobis(1H-indazole)ruthenate (III)], wherein M is an alkali metal cation, comprising:

dissolving indazolium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] in an aqueous solution or a mixture of an aqueous solution and a first organic solvent which is water soluble;

reacting said indazolium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] with an inorganic salt of said alkali metal cation M to form the compound M[tetrachlorobis(1H-indazole)ruthenate (III)] and an inorganic salt of indazole; and

extracting said indazole from said M[tetrachlorobis(1H-indazole)ruthenate (III)] with a second organic solvent which is not substantially water soluble.

3. The method of claim 2 , wherein M is sodium, and said inorganic salt of said alkali metal cation M is sodium dihydrogenphosphate.

4. A method of making the compound sodium trans [tetrachlorobis(1H-indazole)ruthenate (III)], comprising the steps of,

reacting, in an aqueous solution optionally in admixture with a first organic solvent which is water soluble, indazolium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] with an inorganic salt of sodium, to form the compound sodium trans [tetrachlorobis(1H-indazole)ruthenate (III)] and an inorganic salt of indazole; and

removing said indazole from said sodium trans [tetrachlorobis(1H-indazole)ruthenate (III)] by extraction with a second organic solvent which is not substantially water soluble.

5. A method of making the compound sodium trans [tetrachlorobis(1H-indazole)ruthenate (III)], comprising the steps of,

(1) reacting, in an aqueous solution optionally in admixture with a first organic solvent chosen from acetone or THF or a mixture thereof, indazolium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] with NaH 2 PO 4 , to form the compound sodium trans [tetrachlorobis(1H-indazole)ruthenate (III)] and a dihydrophosphate salt of indazole;

(2) removing said indazole from said sodium trans [tetrachlorobis(1H-indazole)ruthenate (III)] by extraction with CH 2 Cl 2 ;

(3) extracting the sodium trans [tetrachlorobis(1H-indazole)ruthenate (III)] resulted from step (2) with ethyl acetate under saturation with NaCl; and

(4) precipitating the sodium trans [tetrachlorobis(1H-indazole)ruthenate (III)] from step (3) by addition of diethyl ether.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 3, 2013
From: NIIKI PHARMA INC.
To: NIIKI PHARMA AQUISITION CORP. 2
Reel/Frame 030740/0100 →
Continuity (3)
Continuation PCTUS2008066456 · Jun 10, 2008
Provisional Application 60943283 · Jun 11, 2007
Related Publication 20100094019A1 · Apr 15, 2010